ACE and Hyperglycemia: Notably, the association remained also significant after adjustments for both glucose control assessed by HbA1c levels and anti-hypertensive and glucose-lowering treatments thus arguing against the possibility that factors affecting DDAH2 expression or activity such as hyperglycemia, and treatments with angiotensin-converting enzyme (ACE) inhibitors, metformin, or pioglitazone, may explain the present results [31, 34–36].